245 related articles for article (PubMed ID: 21372205)
1. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.
Yang X; Popescu NC; Zimonjic DB
Cancer Res; 2011 Apr; 71(8):2916-25. PubMed ID: 21372205
[TBL] [Abstract][Full Text] [Related]
2. CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth.
Kim TY; Jackson S; Xiong Y; Whitsett TG; Lobello JR; Weiss GJ; Tran NL; Bang YJ; Der CJ
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):16868-73. PubMed ID: 24082123
[TBL] [Abstract][Full Text] [Related]
3. DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.
Joshi R; Qin L; Cao X; Zhong S; Voss C; Min W; Li SSC
J Biol Chem; 2020 Jan; 295(2):645-656. PubMed ID: 31806702
[TBL] [Abstract][Full Text] [Related]
4. The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1.
Sanchez-Solana B; Wang D; Qian X; Velayoudame P; Simanshu DK; Acharya JK; Lowy DR
Mol Cancer; 2021 Nov; 20(1):141. PubMed ID: 34727930
[TBL] [Abstract][Full Text] [Related]
5. Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells.
Yuan BZ; Jefferson AM; Millecchia L; Popescu NC; Reynolds SH
Exp Cell Res; 2007 Nov; 313(18):3868-80. PubMed ID: 17888903
[TBL] [Abstract][Full Text] [Related]
6. Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.
Du X; Qian X; Papageorge A; Schetter AJ; Vass WC; Liu X; Braverman R; Robles AI; Lowy DR
Cancer Res; 2012 Sep; 72(17):4405-16. PubMed ID: 22693251
[TBL] [Abstract][Full Text] [Related]
7. Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation.
Ko FC; Ping Yam JW
Int J Cancer; 2014 Jul; 135(2):264-9. PubMed ID: 24114040
[TBL] [Abstract][Full Text] [Related]
8. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO
Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057
[TBL] [Abstract][Full Text] [Related]
9. Tensin1 positively regulates RhoA activity through its interaction with DLC1.
Shih YP; Sun P; Wang A; Lo SH
Biochim Biophys Acta; 2015 Dec; 1853(12):3258-65. PubMed ID: 26427649
[TBL] [Abstract][Full Text] [Related]
10. The Annexin A2/S100A10 Complex: The Mutualistic Symbiosis of Two Distinct Proteins.
Bharadwaj A; Kempster E; Waisman DM
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944495
[TBL] [Abstract][Full Text] [Related]
11. The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation.
Scholz RP; Gustafsson JO; Hoffmann P; Jaiswal M; Ahmadian MR; Eisler SA; Erlmann P; Schmid S; Hausser A; Olayioye MA
Exp Cell Res; 2011 Feb; 317(4):496-503. PubMed ID: 21087603
[TBL] [Abstract][Full Text] [Related]
12. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.
Chan LK; Ko FC; Ng IO; Yam JW
PLoS One; 2009; 4(5):e5572. PubMed ID: 19440389
[TBL] [Abstract][Full Text] [Related]
13. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.
Tripathi BK; Grant T; Qian X; Zhou M; Mertins P; Wang D; Papageorge AG; Tarasov SG; Hunter KW; Carr SA; Lowy DR
J Cell Biol; 2017 Dec; 216(12):4255-4270. PubMed ID: 29114068
[TBL] [Abstract][Full Text] [Related]
14. Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin.
MacLeod TJ; Kwon M; Filipenko NR; Waisman DM
J Biol Chem; 2003 Jul; 278(28):25577-84. PubMed ID: 12730231
[TBL] [Abstract][Full Text] [Related]
15. S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors.
Kwon M; MacLeod TJ; Zhang Y; Waisman DM
Front Biosci; 2005 Jan; 10():300-25. PubMed ID: 15574370
[TBL] [Abstract][Full Text] [Related]
16. Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11.
He KL; Deora AB; Xiong H; Ling Q; Weksler BB; Niesvizky R; Hajjar KA
J Biol Chem; 2008 Jul; 283(28):19192-200. PubMed ID: 18434302
[TBL] [Abstract][Full Text] [Related]
17. SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions.
Tripathi BK; Anderman MF; Qian X; Zhou M; Wang D; Papageorge AG; Lowy DR
J Cell Biol; 2019 Sep; 218(9):3060-3076. PubMed ID: 31308216
[TBL] [Abstract][Full Text] [Related]
18. Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer.
Gökmen-Polar Y; True JD; Vieth E; Gu Y; Gu X; Qi GD; Mosley AL; Badve SS
PLoS One; 2018; 13(10):e0204658. PubMed ID: 30278072
[TBL] [Abstract][Full Text] [Related]
19. Multiple functions of S100A10, an important cancer promoter.
Saiki Y; Horii A
Pathol Int; 2019 Nov; 69(11):629-636. PubMed ID: 31612598
[TBL] [Abstract][Full Text] [Related]
20. Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10.
Madureira PA; Bharadwaj AG; Bydoun M; Garant K; O'Connell P; Lee P; Waisman DM
Oncotarget; 2016 Jul; 7(30):47720-47737. PubMed ID: 27351226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
